2026 · 1st Quarter (Jan 1 - Mar 31)
Filed by CROSSROADS STRATEGIES, LLC.
Open official filingSource-reported fields
Literal source text
Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; pharmaceutical scheduling; TRICARE coverage issues in FY2027 National Defense Authorization Act; PBM reform; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
Literal federal measure citations: S.891
General issues related to Medicare and Medicaid, including: Part D Medicare Program; CMMI Drug Pricing Demonstration Programs; drug pricing.
Issues related to tax reform; R&D tax credit; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
Literal federal measure citations: H.R.1
Issues related to supply chain and tariffs; Section 232 tariff investigation on branded pharmaceuticals.
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.
